Breaks Categories: News

MondayApr 08, 2019 12:33 pm

NetworkNewsBreaks – GENFIT S.A. (NASDAQ: GNFT) Secures Gross Proceeds of Approximately $155.4 Million through Initial Public Offering

French biopharmaceutical company GENFIT S.A. (NASDAQ: GNFT) recently closed its initial public offering of 7,647,500 new ordinary shares, including an additional 997,500 ADSs pursuant to the full exercise of the over-allotment option granted to the underwriters. The offering, which resulted in gross proceeds of approximately $155.4 million for GENFIT S.A., was comprised of 7,147,500 American Depositary Shares, each representing one ordinary share (“ADSs”), at a public offering price of $20.32 per ADS, and a concurrent private placement of 500,000 ordinary shares in Europe (including France) and countries outside of the United States at the corresponding offering price of €18.00 per…

Continue Reading

MondayApr 08, 2019 11:46 am

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…

Continue Reading

MondayApr 08, 2019 10:14 am

NetworkNewsBreaks – Generation Alpha Inc. (GNAL) Purchases Arizona Cultivation Facility in Effort to Fast-Track Operations in US Medical Cannabis Sector

Vertically integrated cannabis technology innovator, manufacturer and distributor Generation Alpha Inc. (OTCQB: GNAL) this morning announced its purchase of a roughly 46,000 sq. ft. facility in Phoenix, Arizona. According to the update, the facility is approved with a special use permit (“SUP”) for the cultivation and processing of medical cannabis and is ideally located less than 10 miles from Phoenix’s Sky Harbor International Airport. “This is an incredible deal for Generation Alpha,” GNAL CEO Alan Lien commented in the news release. “This facility, which has been locally permitted for medical cannabis cultivation and processing, will allow us to fast track…

Continue Reading

MondayApr 08, 2019 9:46 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) QuadSight Named ‘Gold Winner’ at 2019 Edison Awards

Automotive technology innovator Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) this morning announced that its QuadSight vision system was recognized at the prestigious 2019 Edison Awards, being named the ‘Gold Winner’ of the ‘Transportation & Logistics, Autonomous Vehicles’ category. Named after Thomas Alva Edison, the awards recognize and honor the world’s best innovators and innovations. A judging panel of more than 3,000 professionals from a wide range of organizations operating in the fields of product development, design, engineering, science, marketing and education selected Foresight’s QuadSight quad-camera stereoscopic vision system for this honor. The system adapts field-proven security technology that…

Continue Reading

MondayApr 08, 2019 9:30 am

NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Featured in Poster Presentation at The European Conference on Neuroinflammation

INmune Bio (NASDAQ: INMB) this morning announced that Lesley Probert, Ph.D., Head of Immunology Department at the Hellenic Pasteur Institute in Athens, Greece, will be presenting a poster about new data on INmune’s neurodegenerative disease drug candidate XPro1595 at The European Conference on Neuroinflammation on April 8th and 9th. The presentation is titled “Selective inhibition of soluble TNF promotes macrophage phagocytosis of myelin debris and remyelination of demyelinated lesions” and will shine a light on how XPro1595 promotes remyelination in animal models of Multiple Sclerosis (“MS”), as demonstrated in Dr. Probert’s earlier work. “The work done by Dr. Probert and…

Continue Reading

MondayApr 08, 2019 9:29 am

NetworkNewsBreaks – SinglePoint Inc. (SING) Files First Annual Report with SEC, Reports 344% YOY Revenue Increase

SinglePoint Inc. (OTCQB: SING), a fully reporting technology company providing mobile payments, ancillary cannabis services and renewable energy solutions, this morning announced the filing of its first annual report with the SEC as a fully reporting issuer. Per the update, SinglePoint ended 2018 with an unaudited sales total of $1,154,671, marking an increase of 344 percent as compared to the previous year. The company attributes this growth to the success of its acquisition strategy. “We have spent a lot of time and effort to put the Company in a position to turn a profit in the very near future. With…

Continue Reading

FridayApr 05, 2019 12:04 pm

NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) Closes C$16 Million Brokered Private Placement

Canada-based cannabis company TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) late Thursday announced that it has closed its previously detailed and upsized brokered private placement of units, generating gross proceeds of C$16 million. Per the update, an aggregate of eight million units of the company were sold at a price of C$2.00 per unit, with each unit comprised of one common share of TransCanna and one half of one common share purchase warrant. TransCanna intends to use the net proceeds of the offering to fund an $8 million down payment for its proposed acquisition of a 196,000-square-foot cannabis facility. The…

Continue Reading

FridayApr 05, 2019 10:56 am

NetworkNewsBreaks – CymaBay Therapeutics, Inc. (NASDAQ: CBAY) Closes Underwritten Public Offering, Realizes Gross Proceeds of Approximately $115M

Clinical-stage biopharmaceutical company CymaBay Therapeutics (NASDAQ: CBAY) has closed an underwritten public offering of 9,200,000 shares of its common stock, which includes an additional 1,200,000 shares pursuant to the full exercise of the over-allotment option. According to the update, CymaBay Therapeutics realized gross proceeds of approximately $115 million resulting from the shares sold at the public offering price of $12.50 per share. The company anticipates using the proceeds to fund ongoing development of seladelpar, as well as for working capital and general corporate purposes. ROTH Capital Partners acted as co-manager for the transaction. To view the full press release, visit…

Continue Reading

FridayApr 05, 2019 10:22 am

NetworkNewsBreaks – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (Frankfurt: YG3) Engages The Design Spot to Further Position in $22B Hemp and CBD Industry

The Yield Growth (CSE: BOSS) (OTCQB: BOSQF) (Frankfurt: YG3) on Thursday announced its appointment of specialist New York Agency The Design Spot for strategic graphic design counsel from overall brand direction to packaging, merchandising and point-of-sale deliverables. According to the update, this move to promote stand-out visual identity and branding is vital to differentiate in the growing hemp-CBD market, which could reach $22 billion by 2022 according to a new estimate from cannabis industry analysts the Brightfield Group. The Design Spot and its team of award-winning designers was chosen for notable experience with an emphasis on skin care, hair care,…

Continue Reading

FridayApr 05, 2019 10:14 am

NetworkNewsBreaks – Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) Announces Upsizing, Closing of Second and Final Tranche of Private Placement

Canadian iron ore exploration and development company Black Iron (TSX: BKI) (OTC: BKIRF) (GR: BIN) this morning announced that it has upsized and closed the second and final tranche of a previously announced non-brokered private placement of units of the company. According to the update and per the second tranche, the company issued 9,043,950 units, each at a price of $0.06, for gross proceeds of $542,637. Combined with the March 29, 2019 closing of the first tranche, Black Iron has issued a total of 26,552,390 units for gross proceeds of $1,593,143. To accommodate investor interest, the company upsized the offering…

Continue Reading